ProteoNova Inc. has patented novel methods that use a proprietary DNA library, in vitro translation, and a novel light activated cross linker to link proteins with their coding messages. The Company’s strong patent portfolio protects the DNA library, the cross linking chemistry, and a specialized bifunctional protein therapeutic system.